STOCK TITAN

Helius Medical Technologies Inc - HSDT STOCK NEWS

Welcome to our dedicated news page for Helius Medical Technologies (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Medical Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Helius Medical Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Helius Medical Technologies's position in the market.

Rhea-AI Summary
Helius Medical Technologies partners with Lovell Government Services to make PoNS device available to federal healthcare systems for MS patients, showing promising real-world results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.49%
Tags
partnership
-
Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) announces Q4 and full year 2023 results, including revenue decline, operational updates, and financial data. The company secured HCPCS codes for PoNS Therapy, expanded stroke program, signed LOI with MSSS, and released study results. Despite revenue decline, operating expenses decreased, and $1.3 million was raised in Q1 2024 under the ATM program. The PR highlights progress towards Medicare reimbursement, stroke patient treatment, and financial stability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
-
Rhea-AI Summary
Helius Medical Technologies, Inc. (NASDAQ: HSDT) announced the release of its fourth quarter and full year 2023 financial results on March 28, 2024. The Company will discuss its progress and plans for the U.S. commercialization of PoNS® during a conference call hosted by its President and CEO, Dane C. Andreeff, and CFO, Jeffrey S. Mathiesen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
Rhea-AI Summary
Helius Medical Technologies, Inc. initiates an open-label study for its registrational program in stroke, focusing on the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in chronic stroke survivors. Enrollment of ten patients at Brooks Rehabilitation marks the beginning of the study, aiming to support U.S. authorization under PoNS's breakthrough designation for stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. to present at the 36th Annual ROTH Conference, showcasing their innovative neuromodulation approach for balance and gait deficits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
conferences
-
Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) achieves a significant milestone with CMS assigning HCPCS Level II codes for PoNS Therapy for MS patients, extending cash runway with recent stock issuances. The company anticipates reimbursement negotiations with third-party payers and potential positive cash flow post-reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.19%
Tags
none
Rhea-AI Summary
Helius Medical Technologies, Inc. announces FDA interaction and clinical program optimization for PoNS Therapy in stroke patients. The company aims to evaluate non-invasive neuromodulation for gait and balance deficits, targeting regulatory submission and marketing authorization by 2025. Real-world evidence demonstrates significant improvement in gait and balance, positioning the company for potential breakthrough designation for stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. expands its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections Meeting to showcase its Portable Neuromodulation Stimulator (PoNS®) and highlight the role of physical therapists in using the therapy to improve gait in people with multiple sclerosis (MS). PoNS-trained physical therapists are now present in 10 states across the US, including those with the highest MS prevalence such as New York, California, and Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) expands registrational program for PoNS Therapy™ with the addition of Brooks Rehabilitation Hospital, bringing the total number of patients to 100. The study focuses on evaluating cranial-nerve non-invasive neuromodulation for gait/balance deficits in chronic stroke survivors, with the goal of achieving U.S. authorization under PoNS’s breakthrough designation for stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) to present at NobleCon 19th Annual Emerging Growth Equity Conference. President and CEO Dane Andreeff to discuss novel therapeutic neuromodulation approach for balance and gait deficits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
Helius Medical Technologies Inc

Nasdaq:HSDT

HSDT Rankings

HSDT Stock Data

5.32M
666.42k
1.06%
10.4%
12.6%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
US
Newtown

About HSDT

helius medical technologies, inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. the company's product is portable neuromodulation stimulator (pons), a medical device in canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. its pons device treats neurostimulation of cranial nerves via the tongue to restore lost function. the company is headquartered in newtown, pennsylvania.